Eli Lilly: Court Rules Against Company In Alimta Vitamin Regimen Patent Lawsuit

(RTTNews) - Eli Lilly and Company (LLY) announced the UK High Court decided the Alimta vitamin regimen patent would not presently be infringed by Actavis marketing pemetrexed trometamol in the UK, France, Italy and Spain with instructions to dilute the product only with dextrose solution.

"We strongly disagree with the ruling by the UK High Court granting a declaration of non-infringement on the Alimta vitamin regimen patents under these circumstances. We plan to seek permission to appeal this ruling," said Michael Harrington, senior vice president and general counsel for Lilly.